RLFTF Quote, Trading Chart, Mondobiotech Holding AG Basel

$0.3582 Last:

-1.86% Change Percent:

$0.359 Open:

$0.3582 Previous Close:

$0.393 High:

$0.34 Low:

8,531,040 Volume:

02/26/2021 04:54:46 pm Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Stock Date	Open Price	Close Price	High	Low	Volume
2021-02-26	0.359	0.3582	0.393	0.34	8,531,040
2021-02-25	0.3997	0.365	0.3999	0.35	11,564,273
2021-02-24	0.4075	0.3893	0.415	0.3825	22,325,799
2021-02-23	0.3699	0.424	0.4999	0.338	46,804,690
2021-02-22	0.4025	0.3698	0.411	0.365	7,806,284
2021-02-19	0.34	0.4018	0.405	0.34	13,022,724
2021-02-18	0.363304	0.3517	0.3699	0.3501	5,452,526
2021-02-17	0.36204	0.3621	0.3698	0.3551	5,828,946
2021-02-16	0.39488	0.36	0.3949	0.35	9,414,658
2021-02-15	0.37	0.3502	0.37	0.334	12,643,651
2021-02-12	0.37	0.3502	0.37	0.334	12,643,651
2021-02-11	0.376728	0.358	0.3846	0.3505	16,401,714
2021-02-10	0.415	0.384	0.415	0.368	20,797,773
2021-02-09	0.434484	0.379	0.45	0.31	104,251,465
2021-02-08	0.59	0.65	0.7	0.57	24,391,855
2021-02-05	0.5	0.5315	0.579	0.5	7,957,133
2021-02-04	0.56	0.52	0.56	0.5103	7,663,727
2021-02-03	0.54	0.524	0.54	0.495	13,426,341
2021-02-02	0.573	0.538	0.573	0.529	10,570,360
2021-02-01	0.557968	0.5649	0.5975	0.525	17,240,720

Stock Information

Mondobiotech Holding AG Basel Company Name:

RLFTF Stock Symbol:

OTC Market:

Get RLFTF Alerts

News, Short Squeeze, Breakout and More Instantly...

RLFTF - NeuroRx Announced that RLF-100(TM) has Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure among Patients with Severe Covid-19 Treated with HFNO at 28 Day Interim Endpoint

GENEVA, SWITZERLAND / ACCESSWIRE / February 24, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in advanced clinical development, announces that NeuroRx, Inc. has reported...
RLFTF - NeuroRx Announces that ZYESAMI(TM) (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint

NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint NeuroRx to File for Emergency Use Authori...
RLFTF - NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI(TM) (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19

NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19 If Authorized for Use, ZYESAMI™ Would be First Treatment Specifical...